Biologics in psoriasis: A quick reference guide
Authors:
- Valencia D. ThomasVTValencia D. Thomas
- F. Clarissa YangFYF. Clarissa Yang
- Joseph C. KvedarJKJoseph C. Kvedar
- 31 August 2005
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 53 (2) , 346-351
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Successful treatment of severe psoriasis and psoriatic arthritis with adalimumabBritish Journal of Dermatology, 2004
- Efalizumab for Patients With Moderate to Severe Plaque PsoriasisJAMA, 2003
- Treatment of Psoriasis With AlefaceptArchives of Dermatology, 2003
- CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized studyJournal of the American Academy of Dermatology, 2003
- Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasisJournal of the American Academy of Dermatology, 2003
- Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementThe Lancet Infectious Diseases, 2003
- Novel immune-based therapies for psoriasisBritish Journal of Dermatology, 2002
- Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T LymphocytesNew England Journal of Medicine, 2001
- Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialThe Lancet, 2001
- Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasisJournal of the American Academy of Dermatology, 2000